RxDoctor Payments Data

Adam Siwek, DO

Interventional Pain Medicine · Phoenix, AZNPI 1770074007

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (38.7%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Abbott at 52.1% of the total. Reporting peaked in 2024 at $8,175 and has fallen 85.3% since, to $1,198 in 2025.

$13,813in general payments, 2019–2025

Across 172 payments — averaging $80.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Medtronic$4K
  • Spinal Simplicity, LLC$919
  • Biotronik NRO, Inc.$310
  • Relievant Medsystems, Inc.$285
  • Boston Scientific$218
  • plus $832 from 14 others

What the payments were for

  • Grants$3,33324%
  • Travel & lodging$5,12937%
  • Food & beverage$5,35139%

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,813 in reported general payments places this provider in the 65th percentile of 64 interventional pain medicine providers in Arizona.

See all interventional pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$322,248
Medicare patients
395
Services billed
7,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen377$10,517
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen234$6,680
Xtampza ErOxycodone Myristate22$6,345
Gabapentin252$3,550
Oxycodone Hcl173$2,447
Pregabalin107$2,433
Morphine Sulfate ErMorphine Sulfate79$1,630
Cyclobenzaprine Hcl116$1,588
Methocarbamol87$1,374
Tizanidine Hcl114$1,279
Tramadol Hcl126$1,102
Morphine Sulfate25$873
Diclofenac Sodium28$848
Celecoxib29$794
Baclofen41$770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$31$6,34522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 64 interventional pain medicine providers in Arizona.

Other interventional pain medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →